Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab

Pontes, Caridad; Zara, Corinne; Torrent-Farnell, Josep; Obach, Merce; Nadal, Cristina; Vella-Bonanno, Patricia; Ermisch, Michael; Simoens, Steven; Hauegen, Renata Curi; Gulbinovic, Jolanta; Timoney, Angela; Martin, Antony P.; Mueller, Tanja; Nachtnebel, Anna; Campbell, Stephen; Selke, Gisbert; Bochenek, Tomasz; Rothe, Celia C.; Mardare, Ileana; Bennie, Marion; Fürst, Jurij; Malmstrom, Rickard E.; Godman, Brian

This article is a Preprint

Preprints are preliminary research reports that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Preprints posted online allow authors to receive rapid feedback and the entire scientific community can appraise the work for themselves and respond appropriately. Those comments are posted alongside the preprints for anyone to read them and serve as a post publication assessment.

Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab

Pontes, Caridad; Zara, Corinne; Torrent-Farnell, Josep; Obach, Merce; Nadal, Cristina; Vella-Bonanno, Patricia; Ermisch, Michael; Simoens, Steven; Hauegen, Renata Curi; Gulbinovic, Jolanta; Timoney, Angela; Martin, Antony P.; Mueller, Tanja; Nachtnebel, Anna; Campbell, Stephen; Selke, Gisbert; Bochenek, Tomasz; Rothe, Celia C.; Mardare, Ileana; Bennie, Marion; Fürst, Jurij; Malmstrom, Rickard E.; Godman, Brian.

Affiliation

Pontes, Caridad; Drug Area, Catalan Health Service. Barcelona, Spain / Department of Pharmacology. Therapeutics and Toxicology. Universitat Autònoma de Barcelona. Barcelona, Spain..

Preprint in English | Fiocruz Preprints | ID: ppf-31008